Kamada (NASDAQ:KMDA) Shares Cross Above Fifty Day Moving Average – Time to Sell?
by Tristan Rich · The Markets DailyKamada Ltd. (NASDAQ:KMDA – Get Free Report) passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $8.31 and traded as high as $9.09. Kamada shares last traded at $8.98, with a volume of 56,942 shares.
Analyst Ratings Changes
A number of research analysts have recently commented on KMDA shares. HC Wainwright boosted their price target on shares of Kamada from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Wall Street Zen upgraded Kamada from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Weiss Ratings reissued a “buy (b-)” rating on shares of Kamada in a research note on Thursday, January 22nd. Finally, Benchmark restated a “buy” rating on shares of Kamada in a research report on Thursday, January 8th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Kamada presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.
View Our Latest Stock Analysis on Kamada
Kamada Stock Up 1.4%
The firm has a market capitalization of $516.44 million, a P/E ratio of 24.95, a price-to-earnings-growth ratio of 0.75 and a beta of 0.94. The firm’s 50-day simple moving average is $8.31 and its 200-day simple moving average is $7.42.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new position in Kamada in the first quarter valued at $206,000. NewEdge Advisors LLC lifted its stake in Kamada by 119.9% during the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 28,165 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Kamada in the 1st quarter worth about $497,000. Jane Street Group LLC purchased a new position in shares of Kamada in the 1st quarter worth about $582,000. Finally, Acadian Asset Management LLC increased its position in shares of Kamada by 3.1% during the 2nd quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company’s stock valued at $2,053,000 after purchasing an additional 7,925 shares during the last quarter. 20.38% of the stock is currently owned by hedge funds and other institutional investors.
About Kamada
Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.
Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.